Recombinant Anti-CTLA4 Fab Antibody
Product Sizes
50 ug
£543.00
400-001-MT1-50UG
About this Product
- SKU:
- 400-001-MT1
- Additional Names:
- CTLA4|Cytotoxic T-Lymphocyte Associated Protein 4, Ipilimumab, Yervoy, recombinant Monoclonal CTLA4, RabMAb CTLA4, CTLA-4, CD152, Insulin-Dependent Diabetes Mellitus 12, Cytotoxic T-Lymphocyte Protein 4, Celiac Disease 3, GSE, CD, Ligand And Transmembrane Spliced, Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4
- Application:
- ELISA, Flow Cytometry, Western Blot
- Buffer:
- 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride
- CE/IVD:
- RUO
- translate.label.attr.clone:
- Abz521
- Clonality:
- Recombinant Monoclonal
- Extra Details:
- CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation - a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis. This antibody is made from a humanized Fab fragment of anti-CTLA4, ipilimumab or Yervoy, the first FDA approved immune checkpoint blockade therapy for cancer treatment. Humanized Recombinant Anti-CTLA4 fragment Antibody is useful for researchers interested in cancer research, immunodeficiency, and autoimmune diseases.
- Formulation:
- 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
- Host:
- Human
- Immunogen:
- CTLA4
- Isotype:
- IgG, IgG1
- Physical State:
- Liquid
- Reactivities:
- Human
- Shipping Conditions:
- Blue Ice
- Specificity:
- Humanized Recombinant CLTA4 Fab fragment was expressed in HEK293 cells. Purified using one-step purification by HisTrap FF Crude. The purity was estimated to be >95% by SDS-PAGE analysis.
- Storage Conditions:
- -20[o]C
- Supplier:
- Rockland Inc
- Type:
- Antibody: Recombinant Antibodies
- Manufacturer's Data Sheet:https://www.rockland.com/search/?searchString=400-001-MT1
